# US 2026/0199242 A1 · Processes for making cyclic lipid implants for intraocular use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0199242 A1
- Document ID: US20260199242A1
- Status: Published application
- Kind: A1
- Application number: 19/378,674
- Filed: 2025-11-04
- Published: 2026-07-16
- Earliest claimed: 2006-12-19
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Lon T. Spada; James N. Chang; Michelle H. Luu
- Web page: https://patentgrep.com/patent/US20260199242A1

## CPC

- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61P 27/12: for cataracts
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61K 9/141: {Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers ((co) spray-dried products A61K9/16, (co) lyophilised products A61K9/19; the carrier being chemically bound to the active ingredient A61K47/50)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.

## Claims

### Claim 1

A low temperature process for making an intraocular implant, the process comprising the steps of:
(a) combining a cyclic lipid therapeutic agent and a polymer to form a mixture;
(b) heating the mixture to a temperature between about 50° C. and about 80° C., and;
(c) extruding the heated mixture, thereby making an implant suitable for intraocular use.

### Claim 2 (depends on 1)

The process of claim 1, wherein the cyclic lipid therapeutic agent is selected from the group consisting of prostaglandins, prostaglandin analogs, and mixtures thereof.

### Claim 3 (depends on 1)

The process of claim 1, wherein the cyclic lipid therapeutic agent is selected from the group consisting of bimatoprost, bimatoprost analogs, latanoprost, latanoprost analogs, travoprost, travoprost analogs, unoprostone, unoprostone analogs, prostaglandin E1 and prostaglandin E1 analogs, prostaglandin E2 and prostaglandin E2 analogs, and mixtures thereof.

### Claim 4 (depends on 3)

The process of claim 3, wherein the cyclic lipid therapeutic agent is selected from the group consisting of bimatoprost, bimatoprost analogs, and mixtures thereof.

### Claim 5 (depends on 1)

The process of claim 1, wherein the polymer is a biodegradable polymer.

### Claim 6 (depends on 5)

The process of claim 5, wherein the biodegradable polymer is selected from the group consisting of polylactic acid, polyglycolic acid, polylactide-co-glycolide, and copolymers thereof.

### Claim 7 (depends on 1)

The process of claim 1, wherein the polymer comprises from about 30% to about 95% by weight of the implant.

### Claim 8 (depends on 1)

The process of claim 1, wherein the cyclic lipid therapeutic agent comprises from about 5% to about 70% by weight of the implant.

### Claim 9 (depends on 1)

The implant made by the process of claim 1.

### Claim 10

A process for making an intraocular implant, the process comprising the steps of:
(a) combining:
(i) a cyclic lipid therapeutic agent;
(ii) a first biodegradable polymer, and;
(iii) a second biodegradable polymer to form a mixture,
wherein;
(α) the first biodegradable polymer and the second biodegradable polymer are different polymers;
(β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are substantially similar, and;
(γ) the melt temperature of the second biodegradable polymer is lower than the melt transition temperature of the first biodegradable polymer,
(b) heating the mixture to the lower melt temperature of the second biodegradable polymer, so that the second biodegradable polymer can function as a solvent for the cyclic lipid therapeutic agent and for the first biodegradable polymer, wherein the melt temperature of the second biodegradable polymer is lower than the temperature at which the cyclic lipid therapeutic agent exhibits a substantial loss of potency, and;
(c) extruding the heated mixture, thereby making an implant suitable for intraocular use.

### Claim 11 (depends on 10)

The process of claim 10, wherein the cyclic lipid therapeutic agent component is selected from the group consisting of prostaglandins, prostaglandin analogs, and mixtures thereof.

### Claim 12 (depends on 10)

The process of claim 10, wherein the cyclic lipid therapeutic agent is selected from the group consisting of bimatoprost, bimatoprost analogs, and mixtures thereof.

### Claim 13 (depends on 10)

The process of claim 10 wherein the first biodegradable polymer is selected from the group consisting of polylactic acid, polyglycolic acid, polylactide-co-glycolide, and copolymers thereof.

### Claim 14 (depends on 10)

The process of claim 10, wherein the second biodegradable polymer is selected from the group consisting of decafluorobutane, poly(isobutylene), poly(hexamethylene adipamide), polypropylene, polyethylene, and polyethylene glycol.

### Claim 15 (depends on 10)

The process of claim 10, wherein the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within about 10 Mpa1/2 of each other.

### Claim 16 (depends on 10)

The process of claim 10, wherein the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within about 15 to 30 Mpa1/2.

### Claim 17 (depends on 10)

The process of claim 10, wherein the first polymer comprises from about 30% to about 90% by weight of the implant; the second polymer comprises from about 50% to about 30% by weight of the implant; and the cyclic lipid therapeutic agent comprises from about 5% to about 30% by weight of the implant.

### Claim 18

A process for making an intraocular implant, the process comprising the steps of:
(a) combining:
(i) a prostaglandin analog, wherein the prostaglandin analog comprises from about 5% to about 30% by weight of the implant;
(ii) a poly(lactide-co-glycolide) copolymer, wherein the poly(lactide-co-glycolide) comprises from about 30% to about 90% by weight of the implant; and
(iii) a second biodegradable polymer to form a mixture, wherein the second biodegradable polymer comprises from about 5% to about 40% by weight of the implant, and
wherein;
(α) the poly(lactide-co-glycolide) copolymer and the second biodegradable polymer are different polymers;
(β) the solubilities of the prostaglandin analog, the poly(lactide-co-glycolide) copolymer, and the second biodegradable polymer are all within about 10 Mpa1/2 of each other, and;
(γ) the melt temperature of the second biodegradable polymer is lower than the melting point of the a poly(lactide-co-glycolide) copolymer,
(b) heating the mixture to the lower melt temperature of the second biodegradable polymer, so that the second biodegradable polymer can function as a solvent for the prostaglandin analog and for the a poly(lactide-co-glycolide) copolymer, and;
(c) extruding the heated mixture, thereby making an implant suitable for intraocular use, wherein the prostaglandin analog released from the implant has a potency of at least about 50%.

### Claim 19 (depends on 1)

A method for treating an ocular condition, the method comprising the step of intraocular administration of the implant made by the process of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the intraocular administration is selected from a location selected from the group consisting of the anterior chamber, the posterior chamber, the vitreous cavity, the choroid, the suprachoroidal space, the subretinal space, the conjunctiva, the subconjunctival space, the episcleral space, the intracorneal space, the epicorneal space, the sclera, the pars plana, surgically-induced avascular regions, the macula, the retina and sub-tenon locations
